Cargando…
Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis
BACKGROUND: Global antiretroviral therapy has entered a new era. Integrase strand transfer inhibitor (INSTI) has become the first choice in acquired immunodeficiency syndrome (AIDS) treatment. Because INSTI has high antiviral efficacy, rapid virus inhibition, and good tolerance. However, INSTIs may...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811997/ https://www.ncbi.nlm.nih.gov/pubmed/35114968 http://dx.doi.org/10.1186/s12879-022-07091-1 |
_version_ | 1784644553268002816 |
---|---|
author | Bai, Ruojing Lv, Shiyun Wu, Hao Dai, Lili |
author_facet | Bai, Ruojing Lv, Shiyun Wu, Hao Dai, Lili |
author_sort | Bai, Ruojing |
collection | PubMed |
description | BACKGROUND: Global antiretroviral therapy has entered a new era. Integrase strand transfer inhibitor (INSTI) has become the first choice in acquired immunodeficiency syndrome (AIDS) treatment. Because INSTI has high antiviral efficacy, rapid virus inhibition, and good tolerance. However, INSTIs may increase the risk of obesity. Each INSTI has its unique impact on weight gain in patients with human immunodeficiency virus (HIV)/AIDS. This study systematically assessed different INSTIs in causing significant weight gain in HIV/AIDS patients by integrating data from relevant literature. METHODS: PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), China Science and Technology Journal Database (VIP), and Wanfang databases were searched to find studies on the influence of different INSTIs in weight gain. Data on weight change were extracted, and a network meta-analysis was performed. RESULTS: Eight studies reported weight changes in HIV/AIDS patients were included. Results of the network meta-analysis showed that the weight gain of HIV/AIDS patients treated with Dolutegravir (DTG) was significantly higher than that of Elvitegravir (EVG) [MD = 1.13, (0.18–2.07)]. The consistency test results showed no overall and local inconsistency, and no significant difference in the results of the direct and indirect comparison was detected (p > 0.05). The rank order of probability was DTG (79.2%) > Bictegravir (BIC) (77.9%) > Raltegravir (RAL) (33.2%) > EVG (9.7%), suggesting that DTG may be the INSTI drug that causes the most significant weight gain in HIV/AIDS patients. CONCLUSION: According to the data analysis, among the existing INSTIs, DTG may be the drug that causes the most significant weight gain in HIV/AIDS patients, followed by BIC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07091-1. |
format | Online Article Text |
id | pubmed-8811997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88119972022-02-03 Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis Bai, Ruojing Lv, Shiyun Wu, Hao Dai, Lili BMC Infect Dis Research Article BACKGROUND: Global antiretroviral therapy has entered a new era. Integrase strand transfer inhibitor (INSTI) has become the first choice in acquired immunodeficiency syndrome (AIDS) treatment. Because INSTI has high antiviral efficacy, rapid virus inhibition, and good tolerance. However, INSTIs may increase the risk of obesity. Each INSTI has its unique impact on weight gain in patients with human immunodeficiency virus (HIV)/AIDS. This study systematically assessed different INSTIs in causing significant weight gain in HIV/AIDS patients by integrating data from relevant literature. METHODS: PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), China Science and Technology Journal Database (VIP), and Wanfang databases were searched to find studies on the influence of different INSTIs in weight gain. Data on weight change were extracted, and a network meta-analysis was performed. RESULTS: Eight studies reported weight changes in HIV/AIDS patients were included. Results of the network meta-analysis showed that the weight gain of HIV/AIDS patients treated with Dolutegravir (DTG) was significantly higher than that of Elvitegravir (EVG) [MD = 1.13, (0.18–2.07)]. The consistency test results showed no overall and local inconsistency, and no significant difference in the results of the direct and indirect comparison was detected (p > 0.05). The rank order of probability was DTG (79.2%) > Bictegravir (BIC) (77.9%) > Raltegravir (RAL) (33.2%) > EVG (9.7%), suggesting that DTG may be the INSTI drug that causes the most significant weight gain in HIV/AIDS patients. CONCLUSION: According to the data analysis, among the existing INSTIs, DTG may be the drug that causes the most significant weight gain in HIV/AIDS patients, followed by BIC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07091-1. BioMed Central 2022-02-03 /pmc/articles/PMC8811997/ /pubmed/35114968 http://dx.doi.org/10.1186/s12879-022-07091-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Bai, Ruojing Lv, Shiyun Wu, Hao Dai, Lili Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis |
title | Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis |
title_full | Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis |
title_fullStr | Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis |
title_full_unstemmed | Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis |
title_short | Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis |
title_sort | effects of different integrase strand transfer inhibitors on body weight in patients with hiv/aids: a network meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811997/ https://www.ncbi.nlm.nih.gov/pubmed/35114968 http://dx.doi.org/10.1186/s12879-022-07091-1 |
work_keys_str_mv | AT bairuojing effectsofdifferentintegrasestrandtransferinhibitorsonbodyweightinpatientswithhivaidsanetworkmetaanalysis AT lvshiyun effectsofdifferentintegrasestrandtransferinhibitorsonbodyweightinpatientswithhivaidsanetworkmetaanalysis AT wuhao effectsofdifferentintegrasestrandtransferinhibitorsonbodyweightinpatientswithhivaidsanetworkmetaanalysis AT dailili effectsofdifferentintegrasestrandtransferinhibitorsonbodyweightinpatientswithhivaidsanetworkmetaanalysis |